Immune landscape of melanoma: Tumor microenvironment, resistance mechanisms, and predictive biomarkers

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 1

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Jan 24, 2026; 17(1): 114913
Published online Jan 24, 2026. doi: 10.5306/wjco.v17.i1.114913

Table 2 Major published clinical trials evaluating combination therapies in advanced melanoma

Combination therapy	Study	Phase	Population	Key outcomes	Ref.
Nivolumab + ipilimumab	CheckMate 067	III	Untreated advanced melanoma	ORR: Approximately 57%; 5-year OS: Approximately 52%	[64,163]
Relatlimab + nivolumab	RELATIVITY-047	II/III	Untreated advanced/metastatic melanoma	PFS: 10.1 months vs 4.6 months (vs nivolumab alone)	[164]
Pembrolizumab + T-VEC (oncolytic virus)	MASTERKEY-265	I-b/III	Unresectable advanced melanoma	ORR: Approximately 62% in phase I-b; phase III did not confirm benefit	[133,165]
Dabrafenib + trametinib + pembrolizumab	KEYNOTE-022	II	BRAF V600-mutant advanced melanoma	Median PFS: 16.9 months vs 10.7 months	[166]
Atezolizumab + vemurafenib + cobimetinib	IMspire150	III	BRAF V600-mutant advanced melanoma	Median PFS: 15.1 months vs 10.6 months	[167]

T-VEC: Talimogene laherparepvec; BRAF: B-Raf proto-oncogene; ORR: Objective response rate; OS: Overall survival; PFS: Progression-free survival.

Citation: Oliveira MMGL, Lemos CS, Brazão MLS, Rodrigues ALA, do Nascimento EDC, Cardoso EMP, Arantes MFF, de Melo FF. Immune landscape of melanoma: Tumor microenvironment, resistance mechanisms, and predictive biomarkers. World J Clin Oncol 2026; 17(1): 114913
URL: https://www.wjgnet.com/2218-4333/full/v17/i1/114913.htm
DOI: https://dx.doi.org/10.5306/wjco.v17.i1.114913

Oliveira MMGL, Lemos CS, Brazão MLS, Rodrigues ALA, do Nascimento EDC, Cardoso EMP, Arantes MFF, de Melo FF. Immune landscape of melanoma: Tumor microenvironment, resistance mechanisms, and predictive biomarkers. World J Clin Oncol 2026; 17(1): 114913 [PMID: 41608340 DOI: 10.5306/wjco.v17.i1.114913]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.